People in the News
Dmitry Samarsky has recently been named director of technology development at Dharmacon.
Previously, Samarsky was with Invitrogen, where he formulated partnership models and helped develop platform solutions for the drug discovery process, according to Dhamacon. Before that, he was with Sequitur, which was acquired by Invitrogen in late 2003 (see
Samarsky holds a PhD from the University of Massachusetts, Amherst.
Products & Services
Kreatech said this week that it has released the small RNA labeling kit.
According to the company, the kit uses ULS labeling technology to directly label any and all sizes of naturally occurring nucleic acids, including microRNAs and siRNAs, without the need of enzymes.